Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.
about
Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffeePsychostimulants and cognition: a continuum of behavioral and cognitive activationHighlights on the development of A(2A) adenosine receptor agonists and antagonistsCaffeine and progression of Parkinson diseaseIdentification of zebrafish A2 adenosine receptors and expression in developing embryosPolymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson's disease in men and women.Preclinical jockeying on the translational track of adenosine A2A receptors.Functional models of Parkinson's disease: a valuable tool in the development of novel therapies.Pathophysiological roles for purines: adenosine, caffeine and urate.Stuck at the bench: Potential natural neuroprotective compounds for concussion.Pathway-specific effect of caffeine on protection against UV irradiation-induced apoptosis in corneal epithelial cells.Adenosine receptor signaling in the brain immune system.Intramembrane receptor-receptor interactions: a novel principle in molecular medicine.The emerging science of precision medicine and pharmacogenomics for Parkinson's disease.Protective effect of aminophylline against cigarette smoke extract-induced apoptosis in human lung fibroblasts (MRC-5 cells).Caffeine, creatine, GRIN2A and Parkinson's disease progression.Cigarette smoking, coffee intake and alcohol consumption preceding Parkinson's disease: a case-control study.[Epidemiology and causes of Parkinson's disease].Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockadeCautionary optimism: caffeine and Parkinson's disease risk.Caffeine as a photoprotective agent for diminishing phototoxicity.Selective inactivation or reconstitution of adenosine A2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury.Cytoprotection against oxidative stress-induced damage of astrocytes by extracellular ATP via P2Y1 receptors.Pharmacokinetics and metabolism of [14C]-tozadenant (SYN-115), a novel A2a receptor antagonist ligand, in healthy volunteers.Modulation of seizures and synaptic plasticity by adenosinergic receptors in an experimental model of temporal lobe epilepsy induced by pilocarpine in rats.Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia.Associations between Lifestyle Factors and Parkinson's Disease in an Urban Sri Lankan Clinic Study.Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis.Differences in Parkinson's Disease Risk with Caffeine Intake and Postmenopausal Hormone Use.Sleep is more sensitive to high doses of caffeine in the middle years of life.Neuroprotective effects of caffeine against complex I inhibition-induced apoptosis are mediated by inhibition of the Atm/p53/E2F-1 path in cerebellar granule neurons.Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease.Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk.Plant-Derived Natural Products for Parkinson's Disease Therapy.Influence of caffeine on 3,4-methylenedioxymethamphetamine-induced dopaminergic neuron degeneration and neuroinflammation is age-dependent.
P2860
Q21092426-957ACC9A-3BBE-4668-9914-EEDD700EEBD4Q22242285-FB27D44F-22C0-4E66-901B-865460DE497BQ28279556-88316663-DDC8-4D09-AD4E-9C768AC52942Q30432945-41A97D66-F37B-4495-A665-4FA1273A577FQ30436906-7247F3A2-D675-41D2-A606-F68E71AE508AQ34044101-7B185B4D-D3F9-49EF-9CE1-18470442BFF9Q34777609-B6205E79-E909-47E8-968D-D1CE17037A14Q34916732-DFD066E6-9DD4-41EA-A154-67D9E9C0E163Q35008049-CD81EE86-31F6-4F03-A732-18BF70F24080Q35493114-22E5812F-68F7-419E-AECE-1350CFEF0957Q35894504-0878DCCA-F42F-46BF-B720-52C35FBF15F4Q36242243-33D06D63-4DD9-4EDC-9C52-5534C194EEF4Q36635157-426C75AA-76ED-4ABB-BA8B-1F8D2EBACE09Q38369889-3F51F6BB-C4BD-47C2-9819-E325E48CA4EEQ38478189-9D8A3470-96C3-4D12-8C6F-5607DF7C254BQ38893103-B6E9C922-B85F-48F5-9559-C204E24E37AFQ39940475-8186147A-2F23-46E5-A5B8-0E8C0C571D9DQ40294127-EF313286-BEC9-4EF1-84F0-FF4410E793E5Q40722338-8FFFC525-C66E-4234-86CC-CCDA3823BC9BQ42740862-2F81992C-AEF4-4193-AFE2-A13BB26E1B19Q42970279-8DC362EA-80DA-436E-A534-D516DD51D416Q45078353-4020E003-7D54-4FFA-8ABC-34644ECDEAA5Q45115517-B3095BEB-0B16-4E44-A8E6-61DCA020C3EFQ46506500-7DBB3700-BB30-4609-B294-998F033D34A3Q46574500-3BD042EC-D476-46AF-8804-DD9CBC33A0F2Q46643979-98357DA4-D8E3-48E3-9ADD-F2AEF4CBFDC6Q47104552-28F27512-4A2C-4202-BB51-1FC857050396Q47627884-A842FA66-F40F-4E83-AEC0-F492EF1B6F0DQ47851272-B96F6185-1369-48D0-ABE5-006D1B95C79CQ47988786-328B0153-E3B6-4AF0-811A-7C386AFDFB4DQ48101711-1A849647-FD98-4CE7-9A3E-46D583727029Q48109639-5BACDC6A-4A7A-47CA-9A7D-D86B45FC7524Q48520930-4CDF7CC8-4527-48BF-90E4-B57DD2EDAC7DQ51800931-F9BDD613-53EB-4FF7-B803-4A805B030F23Q52148359-FA57203A-4FED-4977-9310-6237D198F4C5
P2860
Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Neuroprotection by caffeine an ...... models of Parkinson's disease.
@ast
Neuroprotection by caffeine an ...... models of Parkinson's disease.
@en
type
label
Neuroprotection by caffeine an ...... models of Parkinson's disease.
@ast
Neuroprotection by caffeine an ...... models of Parkinson's disease.
@en
prefLabel
Neuroprotection by caffeine an ...... models of Parkinson's disease.
@ast
Neuroprotection by caffeine an ...... models of Parkinson's disease.
@en
P2093
P1433
P1476
Neuroprotection by caffeine an ...... models of Parkinson's disease.
@en
P2093
Emin Oztas
Jacobus P Petzer
Jiang-Fan Chen
Kay Castagnoli
Neal Castagnoli
P304
P356
10.1212/01.WNL.0000095214.53646.72
P407
P433
11 Suppl 6
P577
2003-12-01T00:00:00Z